Antibacterial agent 138
Antibacterial agent 138 has excellent antibacterial activity to multi-drug resistant bacteria. Antibacterial agent 138 inhibits bacterial protein synthesis but bacterial cell walls.
For research use only. We do not sell to patients.
- CAS No.: 2971788-27-7
- Formula: C34H52INO4S
- Molecular Weight:697.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Antibacterial agent 138 (compound e4) (0.063 μg/mL, 24 h) shows excellent inhibition against MRSA and MRSE[1].
Antibacterial agent 138 has antimicrobial activity against multi-drug resistant bacteria, with MICs ( 0.063-32μg/mL) 16-64 times lower than that of Tiamulin[1].
Antibacterial agent 138 (60 μg/mL, 24 h) shows no signs of cytotoxicity in HEPG2 and HEK293 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:S. aureus, MRSA, S. pneumonia, MRSE, B. subtilis, VRE, K. peneumoniae.
-
Concentration:0-50 μg/mL approximately.
-
Incubation Time:24 h
-
Result:MICs: 0.063, 0.063, <0.031, 0.063, 4, 4, 2 μg/mL
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice model of systemic multi-drug resistant S. aureus infection[1]
-
Dosage:2.5, 5, 10, 20, 40 mg/kg
-
Administration:i.p.
-
Result:Prolonged survival rate.
Reduced bacterial loads in the lungs and liver of infected mice.
Chemical Information
-
CAS No. 2971788-27-7
-
Molecular Weight 697.75
-
Formula C34H52INO4S
-
SMILES
C[C@@H]1[C@]23[C@](C(CC3)=O)([H])[C@]([C@@H](C[C@](C)([C@H]1O)C=C)OC(CSC4=CC=[N+](CCCCCCC)C=C4)=O)([C@@H](CC2)C)C.[I-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)